CORRECTION OF ERROR | 10. CORRECTION OF ERROR On April 16, 2018 the Board of Directors of Vitaxel Group Limited (the “Company”) determined that the Quarterly Reports on Form 10-Q for the periods ended March 31, 2017, June 30, 2017 and September 30, 2017 need to be revised. These revisions are necessary due to errors with respect to the (i) cost of goods sold, (ii) shares issued in January 2017 and in March 2017 and (iii) minor corrections in the revenues. Management noted an error in billing to its related party, Vitaxel Corporation Thailand Co., Ltd, for goods sold to them during the two quarters of fiscal year ended December 31, 2017 which led to the changes in cost of goods sold. It was also discovered that shares issued on January 4, 2017 and on March 21, 2017 were not properly recorded in the Form 10-Q for the period ended March 31, 2017. Due to miscommunications within the Company, the shares issued pursuant to the 2016 Equity Incentive Plan were not recorded. As a result of these errors, cost of goods sold were understated by $3,395, overstated by $25,465 and $51,609 respectively for the periods ended March 31, 2017, June 30, 2017 and September 30, 2017. General and administrative expenses were understated by $3,409,604 for the periods ended March 31, 2017, June 30, 2017 and September 30, 2017. Revenue was understated by $38,925 and $22,236 respectively for the periods ended March 31, 2017 and June 30, 2017, and overstated by $3,713 for the period ended September 30, 2017. Accordingly, the previously filed reports should no longer be relied upon and the Company has revised its Consolidated Balance Sheet as of March 31, 2017, June 30, 2017 and September 30, 2017 and Consolidated Statement of Income and Comprehensive Loss for three months ended March 31, 2017, six months ended June 30, 2017 and nine months ended September 30, 2017. The effect of recording the corrections on certain balance sheet accounts are set forth in the below table. The presentation in the Consolidated Statement of Cash Flows have also been restated accordingly. For 3 months ended March 31, 2017 For Six-Month Period ended June 30, 2017 For Nine-Month Period ended September 30, 2017 Accounts As Reported As Revised As Reported As Revised As Reported As Revised Total Revenue $ 445,178 $ 483,473 $ 535,793 $ 558,029 $ 557,862 $ 554,149 Cost of Revenue (135,589 ) (138,984 ) (203,222 ) (177,757 ) (236,755 ) (185,146 ) Gross Profit 309,589 344,489 332,571 380,272 321,107 369,003 General and administrative expenses (527,060 ) (3,936,664 ) (803,890 ) (4,213,494 ) (1,094,498 ) (4,504,102 ) Loss From Operations (527,161 ) (3,592,276 ) (471,577 ) (3,833,480 ) (774,082 ) (4,135,790 ) Net Loss (207,412 ) (3,582,116 ) (428,141 ) (3,790,044 ) (754,887 ) (4,116,595 ) Total Comprehensive Loss (111,688 ) (3,486,392 ) (655,080 ) (4,016,983 ) (766,906 ) (4,128,614 ) Amount due from an associated company 40,957 79,252 117,156 139,392 112,119 108,406 Accrual and other payables 610,778 614,173 694,100 668,635 660,604 608,995 Additional paid-in capital 1,340,504 4,749,798 1,340,504 4,749,798 1,340,194 4,749,798 Accumulated deficit (2,870,496 ) (6,245,200 ) (2,697,919 ) (6,059,822 ) (2,983,457 ) (6,345,165 ) |